When spinning out a company, one strategy applied by the university or TTO is to often take an equity position in the start-up.
When this happens, how do the university or TTO play their role as a shareholder? Do they keep a close eye on the development of the company and continue to offer active support or do they act more as a sleeping partner? How is the risk measured and what is the exit short-term/long-term strategy chosen by those unusual shareholders?
| Date | Hour | Room | Track |
|---|---|---|---|
| 05th December,2018 | 9:00-10:30 am | Track 2 |
| Speakers |
|---|
|
Adrian Ibrahim - Wellcome Sanger Institute |
|
Caroline Barelle - Elasmogen |
|
Grégoire Franoux - Oxurion (former Thrombogenics) |
|
Pascale Augé - Inserm Transfert |
